This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Upcoming events
-
Interim results for the Six Months Ended 30 June 2022
1st September 2022 -
Jan Jezek, Chief Scientific Officer, speaking at The 17th Annual Peptide Therapeutics Symposium
21st October 2022 - 22nd October 2022
Latest News
-
16th June 2022
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY
-
18th May 2022
ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE
-
28th April 2022
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
News
-
16/06/2022
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY
-
18/05/2022
ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE
-
28/04/2022
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
-
12/04/2022
ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING, INSULIN FOR DIABETES
-
28/03/2022
ARECOR WINS INNOVATION IN BUSINESS AND BUSINESS PERSON OF THE YEAR AWARDS AT THE CAMBRIDGESHIRELIVE BUSINESS AWARDS
-
23/03/2022
ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS
-
20/01/2022
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP